Mauro Delorenzi - Concepedia

Author

Mauro Delorenzi

SIB Swiss Institute of Bioinformatics ORCID

Also Known As

D. Mauro, Delorenzi, M, Delorenzi, Mauro, M Delorenzi, M. DeLorenzi, M. Delorenzi, Mauro DeLorenzi, Mauro Delorenzi, Hong Fang

437

Publications

42.1K

Citations

H-Index

192

Concepts

All Affiliations

SIB Swiss Institute of Bioinformatics University of Lausanne Ludwig Cancer Research École Polytechnique Fédérale de Lausanne University Hospital of Lausanne

About

Mauro Delorenzi is an author at SIB Swiss Institute of Bioinformatics specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	78	21.7K
2	Engineering	11	12	4.2K
3	Natural Sciences	8	9	902
4	Health Sciences	7	7	581
5	Public Health	4	4	280

Mauro Delorenzi

167

Publications

38K

Citations

H-Index

Page 1

	Year	Citations
The consensus molecular subtypes of colorectal cancer Justin Guinney, Rodrigo Dienstmann, Xin Wang, Nature Medicine MedicinePathologyColorectal CancerCancer GenomicsOncology	2015	5K
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Wendy De Roock, Bart Claes, David Bernasconi, The Lancet Oncology Retrospective Consortium AnalysisMedicinePathologyColorectal CancerPik3ca Mutations	2010	2.1K
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis Christos Sotiriou, Pratyaksha Wirapati, Sherene Loi, JNCI Journal of the National Cancer Institute Breast OncologyEngineeringPathologyHistologic GradeCancer Biology	2006	2.1K
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts, New England Journal of Medicine	2016	2K
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer Marc Buyse, Sherene Loi, Laura van’t Veer, JNCI Journal of the National Cancer Institute	2006	1.2K
Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Journal of Clinical Oncology	2009	1.1K
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Antonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, Nature Medicine Cancer ImmunosurveillanceMedicineImmunologyTumor ImmunityCancer Cell Biology	2014	1K
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series Christine Desmedt, Fanny Piette, Sherene Loi, Clinical Cancer Research	2007	968
A comparison of methods for differential expression analysis of RNA-seq data Charlotte Soneson, Mauro Delorenzi BMC Bioinformatics	2013	930
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors Denarda Dangaj Laniti, Marine Bruand, Alizée J Grimm, Cancer Cell Tumor ImmunologyCancer ImmunosurveillanceSolid TumorsImmunologyTumor Immunity	2019	857

Page 1